METHOD OF USING SOLABEGRON
Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Methods of using the pharmaceutical combinations for the treatment of one or more systems associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are al so disclosed.
1 . A method of treating overactive bladder in a subject in need thereof comprising administering to said subject a therapeutically effective amount of solabegron, or a salt, solvate or solvated salt thereof.
2 . The method of claim 1 , wherein the therapeutically effective amount of solabegron is about 50 mg to about 250 mg.
3 . The method of claim 1 , wherein the therapeutically effective amount of solabegron is administered once daily or twice daily.
4 . The method of claim 1 , wherein the therapeutically effective amount of solabegron is selected from the group consisting of 150 mg twice daily, 200 mg twice daily, and 250 mg twice daily.
5 . The method of claim 1 , wherein solabegron is administered orally.
6 . The method of claim 1 , wherein solabegron is administered in a form selected from the group consisting of a tablet and a capsule.
7 . The method of claim 1 , wherein treating overactive bladder is treating a symptom of overactive bladder selected from the group consisting of urgency frequency, frequency of micturition, nocturia, and urinary incontinence.
8 . The method of claim 1 , wherein one or more symptoms of overactive bladder is reduced.
9 . The method of claim 1 , wherein the salt is the hydrochloride salt.
10 . A method of increasing bladder smooth muscle relaxation in a subject in need thereof comprising administering to said subject a therapeutically effective amount of solabegron, or a salt, solvate or solvated salt thereof.
11 . The method of claim 10 , wherein the therapeutically effective amount of solabegron is about 50 mg to about 250 mg.
12 . The method of claim 10 , wherein the therapeutically effective amount of solabegron is administered once daily or twice daily.
13 . The method of claim 10 , wherein the therapeutically effective amount of solabegron is selected from the group consisting of 150 mg twice daily, 200 mg twice daily, and 250 mg twice daily.
14 . The method of claim 10 , wherein solabegron is administered orally.
15 . The method of claim 10 , wherein solabegron is administered in a form selected from the group consisting of a tablet and a capsule.
16 . The method of claim 10 , wherein the salt is the hydrochloride salt.